Human Hepstitis B Immunoglobulin (Ph4) For Intrevenous Injection

Products

Information

Major constituent: Human hepatitis B immunoglobulin; Subsidiary material: Maltose Indications:Use of the product in combination with lamivudine can prevent patients with HBV (hepatitis B virus)-related diseases from being re-infected with HBV after liver transplantation. Strengths:2000 IU (50 IU/ml, 40 ml)
Main Categories
BiopharmaceuticalsContract Services - Analytical & Lab ServicesFinished Dosage Forms
All Categories
BiopharmaceuticalsContract Services - Analytical & Lab ServicesFinished Dosage FormsImmunology
Distribution areas
OceaniaNorth America (USA, Canada)AfricaMiddle East Region (e.g. UAE)Central America (e.g. Mexico)East Asia (e.g. China, Japan, Korea)Europe - EU countriesEurope - non EU (e.g. UK, Russia, ex-CIS countries)South America (e.g. Brazil, Colombia)South Asia (e.g. India, Pakistan, Sri Lanka)South East Asia (e.g. Thailand, Philippines, Singapore)
Supplied from
China
Sichuan Yuanda Shuyang Pharmaceut.Sichuan Yuanda Shuyang Pharmaceutical Co Ltd (Shuyang) was founded in 1985 and now is a subsidiary of China Grand Enterprises, Inc. The total asset of Shuyang is more than 1.5 billion Yuan, with 1.5 billion Yuan of annual sales revenue in 2018. The company has 17 subsidiary plasmapheresis centers. The products are selling all over the country and already entering into international market for 15 years. Shuyang is a leading company for exportation of blood products in China. Shuyang was among the first batch of blood products manufacturers which p...

Log in

See all the content and easy-to-use features by logging in or registering!